Larisa M. Somova

Dr. Larisa M. Somova


Research Focus & Metrics

Academic Career Length

61Years (1966-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2015 in Helicobacter
Verified
Journal Article
Closed access
PDF file
NBNatalya N. Besednova
Natalya N. Besednova
TZTatyana S. Zaporozhets
Tatyana S. Zaporozhets
LSLarisa M. Somova
Larisa M. Somova
Tatyana KuznetsovaTatyana Kuznetsova
Tatyana Kuznetsova

31 January 2014 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Tatyana KuznetsovaTatyana Kuznetsova
Tatyana Kuznetsova
NBNatalya N. Besednova
Natalya N. Besednova
LSLarisa M. Somova
Larisa M. Somova
NPNatalia Plekhova
Natalia Plekhova
An important problem of treating patients with endotoxemia is to find drugs to reduce the negative effects of endotoxin on the organism. We tested fucoidan (sulfated polysaccharide) from the brown alga Fucus evanescens as a potential drug in a mouse model of endotoxemia inducted by lipopolysaccharide (LPS). The survival time of mice injected with LPS increased under fucoidan treatment compared with the group of mice injected with LPS only. The preventive administration of fucoidan to mice with endotoxemia resulted in inhibition of increased levels of proinflammatory cytokines (TNFα and IL-6), as well as decreasing of the processes of hypercoagulability. The parenteral or per os administration of fucoidan resulted in decreasing the degree of microcirculatory disorders and secondary dystrophic-destructive changes in parenchymal organs of mice with endotoxemia. Taken together, these results demonstrate that fucoidan prevents endotoxin-induced damage in a mouse model of endotoxemia and increases the mice’s resistance to LPS.

2 June 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
LSLarisa M. Somova
Larisa M. Somova
FAFedor F. Antonenko
Fedor F. Antonenko
NTNelly F. Timchenko
Nelly F. Timchenko
ILIrina N. Lyapun
Irina N. Lyapun
Pseudotuberculosis in humans until the 1950s was found in different countries of the world as a rare sporadic disease that occurred in the form of acute appendicitis and mesenteric lymphadenitis. In Russia and Japan, the Yersinia pseudotuberculosis (Y. pseudotuberculosis) infection often causes outbreaks of the disease with serious systemic inflammatory symptoms, and this variant of the disease has been known since 1959 as Far Eastern Scarlet-like Fever (FESLF). Russian researchers have proven that the FESLF pathogen is associated with a concrete clonal line of Y. pseudotuberculosis, characterized by a specific plasmid profile (pVM82, pYV 48 MDa), sequence (2ST) and yadA gene allele (1st allele). This review summarized the most important achievements in the study of FESLF since its discovery in the Far East. It has been established that the FESLF causative agent is characterized by a unique phenomenon of psychrophilicity, which consists of its ability to reproduce in the environment with its biologically low and variable temperature (4–12 °C), at which the pathogen multiplies and accumulates while maintaining or increasing its virulence, which ensures the emergence and development of the epidemic process. The key genetic and biochemical mechanisms of Y. pseudotuberculosis adaptation to changing environmental conditions were characterized, and the morphological manifestations of the adaptive variability of these bacteria in different conditions of their habitat were revealed. The main features of the pathogenesis and morphogenesis of FESLF, including those associated with the Y. pseudotuberculosis toxigenicity, were presented. The pathogenetic value of the plasmid PVM82, found only in the FESLF pathogen, was shown.

1 June 2019 in Sovremennye tehnologii v medicine
Verified
Journal Article
Closed access
BABoris Andryukov
Boris Andryukov
LSLarisa M. Somova
Larisa M. Somova
EME.V. Matosova
E.V. Matosova
ILI.N. Lyapun
I.N. Lyapun

3 February 2015 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
LSLarisa M. Somova
Larisa M. Somova
NBN. N. Besednova
N. N. Besednova
NPN. G. Plekhova
N. G. Plekhova
Апоптоз как иммуномодулирующая форма клеточной гибели играет стабилизирующую роль в поддержании оптимального количества клеток в организме. Биологическая сущность гибели клеток при инфекционной патологии освещена недостаточно, а понятие об отрицательном и положительном значении апоптоза в патогенезе болезней представлено неоднозначно. В обзоре основное внимание сосредоточено на классичес ком каспаза-зависимом апоптозе клеток врожденного и адаптивного иммунитета, реактивность которых связана c инициацией и исходом инфекционных процессов. Ряд возбудителей бактериальных и вирусных инфекций способны быть триггерами или ингибиторами апоптоза в эукариотической клетке хозяина, избегая действия факторов иммунной системы. При тяжелых инфекциях, протекающих с развитием сепсиса, фатальное значение имеет массивная апоптотическая потеря лимфоцитов в органах иммунной системы, что приводит к иммунодефицитному состоянию и у многих пациентов соответствует премортальному уменьшению циркулирующих лимфоцитов. Дальнейшие исследования по идентификации молекулярных элементов, с помощью которых патогенные агенты вызывают клеточную гибель, обеспечат разработку новых терапевтических подходов, включая ингибирование апоптоза, для предотвращения прогрессирования тяжелых инфекций.

1 January 2021 in CLINICAL AND EXPERIMENTAL MORPHOLOGY
Verified
Journal Article
Closed access
LSLarisa M. Somova
Larisa M. Somova
EKE.A. Kotsyurbiy
E.A. Kotsyurbiy
EDE.I. Drobot
E.I. Drobot
ILI.N. Lyapun
I.N. Lyapun
Mikhail Yurievich ShchelkanovMikhail Yurievich Shchelkanov
Mikhail Yurievich Shchelkanov
Rapid development in 2020 of the COVID-19 pandemic caused by SARS-CoV-2 initially indicated signifi-cant involvement of the immune system. However, information on specific changes in organs of the immune system is still limited. A wide range of alterations was revealed in our study: from pronounced devastation of B-dependent and T-dependent zones of lymphoid tissue, reminiscent of changes in HIV infection at the AIDS stage, to hyperplasia of the tissue of lymph nodes and spleen of varying degrees. Analyzing the literature data, we focused on the fact that pathomorphological changes revealed in the autopsy studies of patients with a severe COVID-19 were accompanied by premortal lymphopenia in most cases. However, the cause of lymphopenia in COVID-19 has not yet been disclosed, authors of the review hypothesized that unregulated apoptosis of circulating lymphocytes is one of the potential lymphopenia inductors. Cytokine activation (“cytokine storm”) may be associated with lymphoid organs’ atrophy, which also contributes to a decrease in the circulating lymphocyte count. There is no doubt about the relevance of further identification of the immune cell apoptosis as one of the causes of lymphopenia and immune dysfunction in COVID-19 patients, which has prospects for pharmacological developments to manage lymphocytic apoptosis. Keywords: coronavirus infection, COVID-19, pathomorphology, lymphopenia, lymph nodes, spleen, lym-phocytic apoptosis